All contributors
Onconephrology contributor
Leaf, David E
Primarily Anticancer drug nephrotoxicity#30 of 46 recognizedHonor roll
- #5 in Anticancer drug nephrotoxicity
- #3 in Checkpoint-inhibitor kidney injury
25
Clinical papers
1,929
Citations (iCite)
0 / 11
First / senior author
2016–2026
Active years
Output over time
Clinical corpus papers per year — peak 6 in 2021.
- 2016: 2 papers
- 2019: 2 papers
- 2020: 3 papers
- 2021: 6 papers
- 2022: 3 papers
- 2023: 2 papers
- 2024: 2 papers
- 2025: 3 papers
- 2026: 2 papers
20162026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity19
Checkpoint-inhibitor kidney injury12
Onco-nephrology (general)3
Cellular therapy renal effects3
MGRS & paraprotein kidney disease1
Myeloma cast nephropathy1
Frequent co-authors
Other recognized contributors who most often share corpus papers with Leaf (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Leaf among the leading contributors (clinical-paper count on that agent).
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,541-article corpus (regenerated 2026-10-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.